Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein - PubMed

Affiliations

• PMID: 15258191
• DOI: 10.1189/jlb.0504277

Comparative Study

Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein

Fumihiko Hatao et al. J Leukoc Biol. 2004 Oct.

Abstract

Interleukin-1 receptor-associated kinase (IRAK)-4 is a key mediator in the Toll-like receptor (TLR) signaling. We found that stimulation of TLR2, TLR4, or TLR9, but not TLR3, caused a decrease in IRAK-4 protein without affecting its mRNA level in a mouse macrophage cell line, RAW 264. The decrease in IRAK-4 was accompanied by the appearance of a smaller molecular weight protein (32 kD), which was recognized by an anti-IRAK-4 antibody raised against the C-terminal region. The decrease in IRAK-4 and the appearance of the 32-kD protein occurred with slower kinetics than the activation of IRAK-1 and were suppressed by inhibitors of the proteasome, inducible inhibitor of kappaBalpha phosphorylation or protein synthesis, but not by caspase inhibitors. These results indicate that prolonged stimulation of TLR2, TLR4, or TLR9 causes a down-regulation of IRAK-4 protein, which may be mediated through cleavage of IRAK-4 by a protease induced by the activation of nuclear factor-kappaB.

Similar articles

• Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B.

  Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Asehnoune K, et al. J Immunol. 2004 Feb 15;172(4):2522-9. doi: 10.4049/jimmunol.172.4.2522. J Immunol. 2004. PMID: 14764725

• An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.

  Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, Boons GJ, Leibovich SJ. Pinhal-Enfield G, et al. Am J Pathol. 2003 Aug;163(2):711-21. doi: 10.1016/S0002-9440(10)63698-X. Am J Pathol. 2003. PMID: 12875990 Free PMC article.

• Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction.

  Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S. Uematsu S, et al. J Exp Med. 2005 Mar 21;201(6):915-23. doi: 10.1084/jem.20042372. Epub 2005 Mar 14. J Exp Med. 2005. PMID: 15767370 Free PMC article.

• Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members.

  Janssens S, Beyaert R. Janssens S, et al. Mol Cell. 2003 Feb;11(2):293-302. doi: 10.1016/s1097-2765(03)00053-4. Mol Cell. 2003. PMID: 12620219 Review.

• IRAK-4 as the central TIR signaling mediator in innate immunity.

  Suzuki N, Suzuki S, Yeh WC. Suzuki N, et al. Trends Immunol. 2002 Oct;23(10):503-6. doi: 10.1016/s1471-4906(02)02298-6. Trends Immunol. 2002. PMID: 12297423 Review.

Cited by

• Innate pathways to B-cell activation and tolerance.

  Crampton SP, Voynova E, Bolland S. Crampton SP, et al. Ann N Y Acad Sci. 2010 Jan;1183:58-68. doi: 10.1111/j.1749-6632.2009.05123.x. Ann N Y Acad Sci. 2010. PMID: 20146708 Free PMC article. Review.

• MyD88 associated ROS generation is crucial for Lactobacillus induced IL-12 production in macrophage.

  Ichikawa S, Miyake M, Fujii R, Konishi Y. Ichikawa S, et al. PLoS One. 2012;7(4):e35880. doi: 10.1371/journal.pone.0035880. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536449 Free PMC article.

• Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20.

  Xiong Y, Medvedev AE. Xiong Y, et al. J Leukoc Biol. 2011 Dec;90(6):1141-8. doi: 10.1189/jlb.0611273. Epub 2011 Sep 20. J Leukoc Biol. 2011. PMID: 21934070 Free PMC article.

• A mechanistic pharmacodynamic model of IRAK-4 drug inhibition in the Toll-like receptor pathway.

  Nolan RP, Bree AG, Zutshi A. Nolan RP, et al. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):609-22. doi: 10.1007/s10928-013-9334-0. Epub 2013 Sep 26. J Pharmacokinet Pharmacodyn. 2013. PMID: 24097307

• Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.

  Baird AC, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott SL, Lawrance IC, Tulic MK. Baird AC, et al. World J Gastroenterol. 2016 Nov 7;22(41):9104-9116. doi: 10.3748/wjg.v22.i41.9104. World J Gastroenterol. 2016. PMID: 27895398 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • National BioResource Project